Severity
Low
FDA Drug recall · Reported April 26, 2017
Discoloration.
Valeant Pharmaceuticals North America LLC recalled CLENZIderm M.D. Pore Therapy Salicylic Acid 2% Acne Treatment 5 fl. oz. (148 mL), Valeant… - a low-severity action.
CLENZIderm M.D. Pore Therapy Salicylic Acid 2% Acne Treatment 5 fl. oz. (148 mL), Valeant… was recalled by Valeant Pharmaceuticals North America LLC in April 26, 2017. Reason: Discoloration.. Check the official notice for the remedy. Verify recall #D-0672-2017 with the FDA Drug before acting.
The recall
Valeant Pharmaceuticals North America LLC issued this low-severity FDA Drug recall-Discoloration..
Sourced from official FDA Drug enforcement records. Verify recall #D-0672-2017 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0672-2017) was formally reported on April 26, 2017, with the manufacturer initiating the action on March 20, 2017. It is classified under Low severity (Class III), with a current status of Terminated. Valeant Pharmaceuticals North America LLC is listed as the recalling firm, operating out of Bridgewater, NJ. Federal records list the affected scope as 38,767 units.
The documented reason for this recall is: Discoloration. Distribution data in the federal record shows the product reached: nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
38,767 units
Related Recalls
6
5 from same agency
CLENZIderm M.D. Pore Therapy Salicylic Acid 2% Acne Treatment 5 fl. oz. (148 mL), Valeant Pharmaceuticals North America LLC Distributed by OMP, Inc Long Beach, CA 90806 Made in USA. Product SKU 301876102042, NDC 0187-6102-04
Discoloration.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-0672-2017 |
| Date reported | April 26, 2017 |
| Date initiated | March 20, 2017 |
| Recalling firm | Valeant Pharmaceuticals North America LLC |
| Firm location | Bridgewater, NJ |
| Affected scope | 38,767 units |
| Distribution | nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported April 26, 2017. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.